Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 3Pancreatic Neoplasms 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Peripheral Nervous System Diseases 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Hodgkin Disease 1Healthy Adult Participants 1Colorectal Neoplasms 1Colorectal Neoplasia 1Chemotherapy Effect 1Burkitt Lymphoma 1Breast Neoplasms, Male 1Advanced Solid Tumors 1

Interventions

Rituximab 86Cyclophosphamide 80Prednisone 47Doxorubicin 43Lenalidomide 37Vincristine 34Magnetic Resonance Spectroscopy 29polatuzumab vedotin 28Gemcitabine 26Etoposide 26Specimen Handling 25fludarabine 23Biopsy 21Oxaliplatin 20CT-P10 20glofitamab 16tafasitamab 15obinutuzumab 15ibrutinib 13fludarabine phosphate 13zanubrutinib 12axicabtagene ciloleucel 12Immunotherapy, Adoptive 12Ifosfamide 12venetoclax 11pembrolizumab 11deltacortene 11prednylidene 10Prednisolone 10Leukapheresis 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Omeprazole × 1 year × Clear all
NCT00001337 2025-06-22

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
348 enrolled 15 charts
Lymphoid

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡